U.K.'s NICE Rejects Lucentis For Macular Edema; Avastin Remains Poised For Appraisal
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE's preliminary rejection of Lucentis for macular edema paves the way for cheaper Avastin to swallow up most of the U.K. market.
You may also be interested in...
NICE OK For Bayer’s Eylea In AMD May Spell U.K. Trouble For Lucentis
NICE has given the thumbs-up to Bayer’s Eylea in wet AMD, but its impressive cost-effectiveness could spell trouble for Novartis’ Lucentis in the long run.
NICE Nod To Lucentis For ME Raises Unlicensed Comparator Issue
The U.K.’s cost watchdog NICE has waved through Novartis’ Lucentis for macular edema after the Swiss manufacturer offered a discount.
Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema
NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.